BioCentury
ARTICLE | Clinical News

Angiotech Phase I/II paclitaxel results

February 25, 2000 8:00 AM UTC

ANPI said that in the extended treatment phase of its 29-patient Canadian Phase I/II trial of paclitaxel to treat secondary progressive multiple sclerosis, 95 percent of patients remained stable or im...